PCPA 2002-Transparency

Registrant Training June 27, 2006

Valerie Robertson Ph.D.





Santé

Canada

Transparency Overview




Confidential Business Information

- Defined in PCPA {S 43(4) &(5)} as information designated by the provider and that concerns:
 - Manufacturing & quality control processes
 - Methods for determining composition of the product
 - Value of sales, other financial /commercial info.
 - Identity & concentration of formulants & contaminants EXCEPT those on List of Formulants & Contaminants of Concern (Canada Gazette II, December 2005)
- PMRA must verify the CBI designations & notify the applicant/registrant if it does not meet the definition {S 43(6)&(7)}









Modifying provisions { PCP Regs 14(1)}:

When a conditional registration granted :

- Consultation, access to test data and reconsideration opportunity are delayed until confirmatory data submitted & evaluated, or until registration renewed (whichever comes first) i.e., no consultation or decision documents for conditional registration decisions on new actives or major new uses when a conditional registration
- However, evaluation report will be available








- If the registration application is withdrawn before registration, or registration is denied
 - Evaluation report, test data etc will not be put in the Register, the e-public registry or the Reading Room









Additional Information Considered

Act provides authority to consider additional information in an evaluation {S 7(5),19(1)},

• *ie., not supplied by applicant/registrant;*

- Reference in evaluation report satisfies the requirement to place in the Register {PCPRegs S.10}
- Must allow applicant/registrant an opportunity to "make representations" on it before evaluation complete {7(5),19(1)}
 - If info. confidential to the provider, registrant must submit an affidavit agreeing to return it & not copy, share or use it for any other purpose







Inspection of Test Data

- Data that is relevant to the decision
 - Accessible for inspection at time of decision
 - View access via a Reading Room in Ottawa
 - Data continues to be protected by ATI Act, inspection does NOT put the data in the public domain; no copy can be made (S 43(8))
- Requires an application with an affidavit
 - stating the purpose & that there is no intent to use the data or make it available to others for registering/amending a pesticide anywhere (S 43(1))
- PMRA must notify registrant of inspection







Inspection of Test Data

Reading Room security:

- Test data viewable electronically on computer with no external connections
- Copying, taking pictures etc will not be allowed
- Obtaining copies not allowed (by Act)
- Supervision by a PMRA employee
- Note taking will be allowed for purpose of working up an argument to support an objection to a decision







Transitional Provisions

Section 81 states that the Act applies to:

- Applications received before "in force" date if decision not yet reached
 - i.e., applies to submissions in progress
- Products registered on "in force" date
 - EXCEPT that test data supporting decisions made before the "in force" date not accessible until the product is consulted on under the new Act via a major new use application or re-evaluation, or when studies are cross-referenced in a new application
 - and then only the data relevant to the new decision will be put in the Register & be made accessible





What Does Not Change

- For new actives, major new uses, reevaluations (PRDD/PACR):
 - Consultation document (now publish the PRDD/PACR)
 - Decision document (now publish the RDD/RRD)







What is New

- Application receipt & outcome made public
 - New form for reporting proposed new uses
- Permission to publish consultation doc. not required
 - But, error correction step will be incorporated
- Evaluation report made public
 - For new actives, major new uses, re-evaluation will be similar to the consultation document /Reg Note
 - For other submissions with data it will be a short integrated summary of the evaluation (a few pages).
 - Will not include CBI or personal information (Privacy Act)
 - Will include a reference list of test data & additional information considered







What is New

Confidential test data available for inspection

- CBI must be designated by applicant/registrant & verified by PMRA {S 43(4),(5),(6),(7)}:
- For new test data, CBI must also be segregated
- Directives re. designation/segregation methodologies/processes published
 - DIR 2006-03 & DIR 2006-04
 - E-Index Builder Tool for submitting index & e-docs
- Opportunity for public to request reconsideration of major decisions







Transition Challenges

Transparency is:

- New for Industry, the PMRA and the public
- Involves increased workload for industry & the PMRA
- Involves new processes & new electronic tools

CBI protection

- Applicant/registrant designation & segregation in test data submitted under the new Act
- Applicant designation required for previously submitted data; PMRA will segregate
- PMRA can only protect CBI if designated & verified
 - Need to work together to accomplish this PMRA help available
 - Time constraints







E- Public Registry on Day 1

What will you see?

- Single Public registry on PMRA Site with:
 - Listing of "open" registration applications with active etc.
 - Listing of all actives for which re-evaluation started but not yet completed
 - Listing of all registered products (Labels already viewable via ELSE)
- Evaluation reports/other docs added "as soon as reasonably practicable" after decisions made on applications and re-evaluations







Transparency

QUESTIONS?





